BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012;55:1495-502. [PMID: 22955430 DOI: 10.1093/cid/cis758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Khan MR, Saleem Z, Batool N, Babar M, Shabbir A. Retrospective drug utilization review of meropenem and role of infectious disease pharmacist in specialized cancer care hospital. J Oncol Pharm Pract. [DOI: 10.1177/10781552221077929] [Reference Citation Analysis]
2 Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res 2015;77:2-9. [PMID: 25268145 DOI: 10.1038/pr.2014.143] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 6.6] [Reference Citation Analysis]
3 Hawcutt DB, O’connor O, Turner MA. Adverse drug reactions in neonates: could we be documenting more? Expert Review of Clinical Pharmacology 2014;7:807-20. [DOI: 10.1586/17512433.2014.956090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Paczkowska M, Mizera M, Szymanowska-Powałowska D, Lewandowska K, Błaszczak W, Gościańska J, Pietrzak R, Cielecka-Piontek J. β-Cyclodextrin complexation as an effective drug delivery system for meropenem. Eur J Pharm Biopharm 2016;99:24-34. [PMID: 26592156 DOI: 10.1016/j.ejpb.2015.10.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
5 Mukhopadhyay S, Wade KC, Puopolo KM. Drugs for the Prevention and Treatment of Sepsis in the Newborn. Clin Perinatol 2019;46:327-47. [PMID: 31010563 DOI: 10.1016/j.clp.2019.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Johnson JK, Laughon MM. Antimicrobial Agent Dosing in Infants. Clinical Therapeutics 2016;38:1948-60. [DOI: 10.1016/j.clinthera.2016.06.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Pacifici GM, Allegaert K. Clinical pharmacology of carbapenems in neonates. J Chemother 2014;26:67-73. [PMID: 24090536 DOI: 10.1179/1973947813Y.0000000110] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
8 Rivera-Chaparro ND, Cohen-Wolkowiez M, Greenberg RG. Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol 2017;12:1001-16. [PMID: 28758800 DOI: 10.2217/fmb-2017-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
9 Ramasethu J. Prevention and treatment of neonatal nosocomial infections. Matern Health Neonatol Perinatol 2017;3:5. [PMID: 28228969 DOI: 10.1186/s40748-017-0043-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 7.6] [Reference Citation Analysis]
10 Pineda LC, Watt KM. New antibiotic dosing in infants. Clin Perinatol 2015;42:167-76, ix-x. [PMID: 25678003 DOI: 10.1016/j.clp.2014.10.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
11 Lutsar I, Chazallon C, Trafojer U, de Cabre VM, Auriti C, Bertaina C, Calo Carducci FI, Canpolat FE, Esposito S, Fournier I, Hallik M, Heath PT, Ilmoja ML, Iosifidis E, Kuznetsova J, Meyer L, Metsvaht T, Mitsiakos G, Pana ZD, Mosca F, Pugni L, Roilides E, Rossi P, Sarafidis K, Sanchez L, Sharland M, Usonis V, Warris A, Aboulker JP, Giaquinto C; NeoMero Consortium. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial. PLoS One 2020;15:e0229380. [PMID: 32130261 DOI: 10.1371/journal.pone.0229380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
12 Ganguly S, Edginton AN, Gerhart JG, Cohen-Wolkowiez M, Greenberg RG, Gonzalez D; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee. Physiologically Based Pharmacokinetic Modeling of Meropenem in Preterm and Term Infants. Clin Pharmacokinet 2021. [PMID: 34155614 DOI: 10.1007/s40262-021-01046-6] [Reference Citation Analysis]
13 Yue Y, Chen L, Choonara I, Xiong T, Ojha S, Tang J, Wang Y, Zeng L, Shi J, Wang H, Mu D. Cross-sectional study of drug utilisation in a Chinese neonatal unit. J Int Med Res 2020;48:300060520914197. [PMID: 32468875 DOI: 10.1177/0300060520914197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Smith MJ, Boutzoukas A, Autmizguine J, Hudak ML, Zinkhan E, Bloom BT, Heresi G, Lavery AP, Courtney SE, Sokol GM, Cotten CM, Bliss JM, Mendley S, Bendel C, Dammann CEL, Weitkamp JH, Saxonhouse MA, Mundakel GT, Debski J, Sharma G, Erinjeri J, Gao J, Benjamin DK Jr, Hornik CP, Smith PB, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Antibiotic Safety and Effectiveness in Premature Infants With Complicated Intraabdominal Infections. Pediatr Infect Dis J 2021;40:550-5. [PMID: 33902072 DOI: 10.1097/INF.0000000000003034] [Reference Citation Analysis]
15 Hassan HE, Ivaturi V, Gobburu J, Green TP. Dosage Regimens for Meropenem in Children with Pseudomonas Infections Do Not Meet Serum Concentration Targets. Clin Transl Sci 2020;13:301-8. [PMID: 31692264 DOI: 10.1111/cts.12710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Le J, Bradley JS. Optimizing Antibiotic Drug Therapy in Pediatrics: Current State and Future Needs. J Clin Pharmacol 2018;58 Suppl 10:S108-22. [PMID: 30248202 DOI: 10.1002/jcph.1128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Gonzalez D, Paul IM, Benjamin DK Jr, Cohen-Wolkowiez M. Advances in pediatric pharmacology, therapeutics, and toxicology. Adv Pediatr 2014;61:7-31. [PMID: 25037123 DOI: 10.1016/j.yapd.2014.03.005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Hornik CP, Benjamin DK Jr, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act—Pediatric Trials Network. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates. J Pediatr 2016;178:125-129.e1. [PMID: 27522443 DOI: 10.1016/j.jpeds.2016.07.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
19 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-hady H. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatric Infectious Disease Journal 2017;36:358-63. [DOI: 10.1097/inf.0000000000001445] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
20 Lutsar I, Chazallon C, Carducci FI, Trafojer U, Abdelkader B, de Cabre VM, Esposito S, Giaquinto C, Heath PT, Ilmoja ML, Katragkou A, Lascoux C, Metsvaht T, Mitsiakos G, Netzer E, Pugni L, Roilides E, Saidi Y, Sarafidis K, Sharland M, Usonis V, Aboulker JP; NeoMero Consortium. Current management of late onset neonatal bacterial sepsis in five European countries. Eur J Pediatr 2014;173:997-1004. [PMID: 24522326 DOI: 10.1007/s00431-014-2279-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
21 Miller LE, DeRienzo C, Smith PB, Bose C, Clark RH, Cotten CM, Benjamin DK, Hornik CD, Greenberg RG. Association between neonatal intensive care unit medication safety practices, adverse events, and death. J Perinatol 2021;41:1739-44. [PMID: 33033390 DOI: 10.1038/s41372-020-00857-y] [Reference Citation Analysis]
22 Lima-Rogel V, Olguín-Mexquitic L, Kühn-Córdova I, Correa-López T, Romano-Aguilar M, Romero-Méndez MDC, Medellín-Garibay SE, Romano-Moreno S. Optimizing Meropenem Therapy for Severe Nosocomial Infections in Neonates. J Pharm Sci 2021:S0022-3549(21)00284-7. [PMID: 34089712 DOI: 10.1016/j.xphs.2021.05.019] [Reference Citation Analysis]
23 Aguilera-Alonso D, Escosa-García L, Saavedra-Lozano J, Cercenado E, Baquero-Artigao F. Carbapenem-Resistant Gram-Negative Bacterial Infections in Children. Antimicrob Agents Chemother 2020;64:e02183-19. [PMID: 31844014 DOI: 10.1128/AAC.02183-19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013;32:748-53. [PMID: 23838776 DOI: 10.1097/INF.0b013e31828be70b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
25 Martins FS, Zhu P, Heinrichs MT, Sy SKB. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. Br J Clin Pharmacol 2021;87:1012-23. [PMID: 32638408 DOI: 10.1111/bcp.14456] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Laine N, Kaukonen AM, Hoppu K, Airaksinen M, Saxen H. Off-label use of antimicrobials in neonates in a tertiary children's hospital. Eur J Clin Pharmacol 2017;73:609-14. [PMID: 28101656 DOI: 10.1007/s00228-017-2200-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Van den Anker JN, McCune S, Annaert P, Baer GR, Mulugeta Y, Abdelrahman R, Wu K, Krudys KM, Fisher J, Slikker W, Chen C, Burckart GJ, Allegaert K. Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs. Pharmaceutics 2020;12:E685. [PMID: 32698409 DOI: 10.3390/pharmaceutics12070685] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
28 De Keukeleire S, Borrey D, Decaluwe W, Reynders M. Therapeutic Drug Monitoring of Meropenem in Neonate with Necrotizing Enterocolitis: A Challenge. Case Rep Infect Dis 2016;2016:6207487. [PMID: 27703820 DOI: 10.1155/2016/6207487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 van den Anker JN. How to optimize the evaluation and use of antibiotics in neonates. Early Hum Dev 2014;90 Suppl 1:S10-2. [PMID: 24709446 DOI: 10.1016/S0378-3782(14)70004-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
30 Cirillo I, Vaccaro N, Castaneda-Ruiz B, Redman R, Cossey V, Bradley JS, Allegaert K. Open-Label Study To Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants Less than 12 Weeks in Chronological Age. Antimicrob Agents Chemother 2015;59:4742-9. [PMID: 26014957 DOI: 10.1128/AAC.00485-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
31 Chacón-González C, Rivera-Salgado D, Brenes-Chacón H, Naranjo-Zuñiga G, Ávila-Aguero ML. Use of Meropenem in a Tertiary Pediatric Hospital in Costa Rica and Its Role in the Era of Antimicrobial Stewardship. Cureus 2021;13:e15809. [PMID: 34306876 DOI: 10.7759/cureus.15809] [Reference Citation Analysis]